ESMO 2019: Primary 2-year results of a phase 2 trial for T-VEC neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma
In the largest randomized, open-label trial of neoadjuvant therapy in resectable stage IIIB-IVM1a melanoma, T-VEC improved 2-year relapse-free-survival and overall survival.
Oral presentation (LBA66) by R. Dummer et al.
ESMO 2019: T-VEC in combination with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis
At the 3-year landmark follow-up of a randomized, open-label, phase 2 trial, the T-VEC + Ipi combination continued to provide durable and statistically superior ORR compared with Ipi alone in metastatic melanoma.
Oral presentation (LBA70) by J. A. Chesney et al.
ESMO 2019: Efficacy of T-VEC in melanoma patients with locoregional (LR) recurrence, including in-transit metastases (ITM)
this subgroup analysis of the phase 3 OPTiM study showed that in T-VEC-treated patients with ITM (without lymph node metastases) as site of first recurrence, an ORR of 81% and complete response rate of 36% were observed. In comparison in the overall OPTiM population (stage IIIB-IV melanoma), the ORR was 26% and CR rate was 11%.
Poster 1342P, by M. Middleton et al.
ESMO 2019: Real Life Use of Talimogene laherparepvec in melanoma in centers in Austria and Switzerland
In this real life cohort, treatment with TVEC shows a high overall and complete remission rate with the majority of complete responses being durable.
Poster 343P by C. Hoeller et al.
ASCO 2019: In study 266 (Dummer, et al.), neoadjuvant T-VEC led to a significant improvement in the 1-year RFS rate in patients with resectable advanced melanoma compared with surgery alone (HR, 0.73; 80% CI, 0.56-0.93; P = .048).
Prof. Dummer commented that neoadjuvant T-VEC resulted in a higher pCR rate in resectable melanoma than that observed by the overall clinical response rate and may account for the higher R0 resection rate in the T-VEC arm than the surgery-alone arm.
ASCO 2019: In the OPTIM trial in patients with unresected stage IIIB–IVM1c melanoma, T-VEC improved significantly PFS compared to GM-CSF (Milhelm et al.)
driven primarily by patients with stage IIIB-IVM1a melanoma. This is consistent with previous data showing more pronounced overall survival benefit with T-VEC for local regional disease.
